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Abstract
Background: Alzheimer’s disease (AD) is common and highly heritable with many genes and gene variants
associated with AD in one or more studies, including APOE ε2/ε3/ε4. However, the genetic backgrounds for
normal cognition, mild cognitive impairment (MCI) and AD in terms of changes in cerebrospinal fluid (CSF) levels
of Ab1-42, T-tau, and P-tau181P, have not been clearly delineated. We carried out a genome-wide association study
(GWAS) in order to better define the genetic backgrounds to these three states in relation to CSF levels.
Methods: Subjects were participants in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). The GWAS dataset
consisted of 818 participants (mainly Caucasian) genotyped using the Illumina Human Genome 610 Quad
BeadChips. This sample included 410 subjects (119 Normal, 115 MCI and 176 AD) with measurements of CSF Ab1-
42, T-tau, and P-tau181P Levels. We used PLINK to find genetic associations with the three CSF biomarker levels.
Association of each of the 498,205 SNPs was tested using additive, dominant, and general association models
while considering APOE genotype and age. Finally, an effort was made to better identify relevant biochemical
pathways for associated genes using the ALIGATOR software.
Results: We found that there were some associations with APOE genotype although CSF levels were about the
same for each subject group; CSF Ab1-42 levels decreased with APOE gene dose for each subject group. T-tau
levels tended to be higher among AD cases than among normal subjects. From adjusted result using APOE
genotype and age as covariates, no SNP was associated with CSF levels among AD subjects. CYP19A1 ’aromatase’
(rs2899472), NCAM2, and multiple SNPs located on chromosome 10 near the ARL5B gene demonstrated the
strongest associations with Ab1-42 in normal subjects. Two genes found to be near the top SNPs, CYP19A1
(rs2899472, p = 1.90 × 10
-7) and NCAM2 (rs1022442, p = 2.75 × 10
-7) have been reported as genetic factors related
to the progression of AD from previous studies. In AD subjects, APOE ε2/ε3 and ε2/ε4 genotypes were associated
with elevated T-tau levels and ε4/ε4 genotype was associated with elevated T-tau and P-tau181P levels. Pathway
analysis detected several biological pathways implicated in Normal with CSF b-amyloid peptide (Ab1-42).
Conclusions: Our genome-wide association analysis identified several SNPs as important factors for CSF biomarker.
We also provide new evidence for additional candidate genetic risk factors from pathway analysis that can be
tested in further studies.
Background
Alzheimer’s disease (AD) is the most common cause of
dementia and the most prevalent neurodegenerative disor-
der. An estimated 10 percent of Americans over the age of
65 and half of those over age 85 have AD. More than 4.5
million Americans currently suffer from the disease. In
autosomal dominant early-onset Alzheimer’s disease
(EOAD, age of onset < 60 years), three susceptible genes
(APP, PSEN1,a n dPSEN2)h a v eb e e ni d e n t i f i e d[ 1 , 2 ] .L a t e -
onset AD (LOAD) has ~80% heritability, and is strongly
associated with apolipoprotein E (APOE)[ 3 ] .A P O Eh a s
three major alleles (ε2/ε3/ε4) that have different effects on
the risk of LOAD, with ε4 having between 10 and 30
times of risk of developing AD by 75 years of age [4].
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putative susceptible loci and genetic variants, including
sortilin-related receptor (SORL1) [5,6], death-associated
protein kinase 1 (DAPK1) [7], ubiquilin 1 (UBQLN1)
[8], adenosine triphosphate-binding cassette transporter
1, subfamily A (ABCA1) [9], and low-density lipoprotein
receptor-related protein 6 (LRP6) [10]. Besides these
findings, a large meta-analysis from the AlzGene data-
base [11] reported 598 potential AD-susceptibility
genes. For the past few years, genome-wide genotyping
association studies brought considerable success by
reporting new susceptible loci for AD such as Golgi
membrane protein 1 (GOLM1) [12-15]. Recently two
groups published the two largest LOAD GWAS [16,17];
Harold et al. [16] reported the association of SNPs in
clusterin (CLU) and phosphatidylinositol binding cla-
thrin assembly protein (PICALM), and Lambert et al.
[17] reported association of clusterin (CLU) with LOAD
and additionally reported a novel association with com-
plement component (3b/4b) receptor 1 (CR1). These
new findings have provided valuable insights in the
genetics, neuropathologic mechanisms and pathways
associated with AD.
The cerebrospinal fluid (CSF) components b-amyloid
peptide (Ab1-42), total tau protein (T-tau) and phos-
phorylated tau (P-tau181P) are biomarkers for AD and
can be used to aid in diagnosis and to predict progres-
sion from mild cognitive impairment (MCI) to AD
[18,19]. These biomarkers can potentially be used in
future applications to predict the development of MCI
in cognitively normal subjects, progression to AD in
MCI patients, and to monitor AD progression [20-23].
These biomarkers may also be used to reveal genes that
are important in AD pathogenesis. In the present study,
we assessed the several putative AD genes associated
with CSF biomarkers that were identified from major
public GWAS dataset for Alzheimer’s disease, the Alz-
heimer’sd i s e a s eN e u r o i m a g i n gI n itiative (ADNI). This
initiative is the most comprehensive effort to identify
neuroimaging measures and biomarkers associated with
cognitive and functional changes in healthy elderly peo-
ple and in people who have MCI and AD [24]. The
ADNI data is useful for researchers who are searching
for genes that contribute to the development of Alzhei-
mer’s disease, which currently affects more than 4.5 mil-
lion people in the United States alone. We also
investigated possible associations of CSF biomarkers
(Ab1-42, T-tau, and P-tau181P) with the number of APOE
ε4 allele, age and APOE genotype in order to improve
the characterization of the CSF biomarkers and gen-
ome-wide SNP genotyping data from the ADNI cohort.
This is the first genome-wide association study to use
these AD-related biomarkers to identify genes critical
the pathogenesis of AD.
Methods
Sample
Data used in the preparation of this article were
obtained from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) database http://www.loni.ucla.edu/
ADNI. ADNI was launched in 2003 by the National
Institute on Aging (NIA), the National Institute of Bio-
medical Imaging and Bioengineering (NIBIB), the Food
and Drug Administration (FDA), private pharmaceutical
companies and non-profit organizations, as a $60 mil-
lion, 5-year public-private partnership. The primary goal
of ADNI has been to test whether serial magnetic reso-
nance imaging (MRI), positron emission tomography
(PET), other biological markers, and clinical and neu-
ropsychological assessment can be combined to measure
the progression of mild cognitive impairment (MCI) and
early Alzheimer’s disease (AD). Determination of sensi-
tive and specific markers of very early AD progression is
intended to aid researchers and clinicians to develop
new treatments and monitor their effectiveness, as well
as lessen the time and cost of clinical trials.
The Principle Investigator of this initiative is Michael
W. Weiner, M.D., VA Medical Center and University of
California - San Francisco. ADNI is the result of efforts
of many co-investigators from a broad range of aca-
demic institutions and private corporations, and subjects
have been recruited from over 50 sites across the U.S.
and Canada. The initial goal of ADNI was to recruit 800
adults, ages 55 to 90, to participate in the research –
approximately 200 cognitively normal older individuals
to be followed for 3 years, 400 people with MCI to be
followed for 3 years, and 200 people with early AD to
be followed for 2 years. For up-to-date information see
http://www.adni-info.org.
The GWAS dataset (downloaded from ADNI website
in June 2009) consisted of 243 normal, 235 MCI and
340 AD subjects genotyped using the Illumina Human
Genome 610 Quad BeadChips. 410 of these subjects
(119 Normal, 115 MCI and 176 AD; 247 males and 163
females) have CSF Ab1-42,T - t a u ,a n dP - t a u 181P levels.
Detailed protocols for subject recruitment and biomar-
ker accrual are available at the ADNI website http://
www.adni-info.org/. Demographics, CSF biomarkers, and
APOE genotype data of the ADNI dataset are summar-
ized in Table 1, Table 2 and Additional file 1.
Genotyping and sample quality control
Quality control for the genotyping data was performed
using PLINK http://pngu.mgh.harvard.edu/~purcell/
plink/[25] as follows. 498,205 SNPs were retained after
excluding SNPs with Minor Allele Frequency (MAF) <
5%, call rate < 98%, or significant in Hardy-Weinberg
Equilibrium test (p ≤ 10
-6). All samples had genotyping
call rate > 95% and were retained. We then examined
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first two dimensions from principal components analysis,
using SmartPCA from EIGENSTRAT http://genepath.
med.harvard.edu/~reich/Software.htm[26,27]. Self-
reported ethnicity and racial identities for ADNI subjects
were used to highlight samples in the PCA plot and are
summarized in Additional file 2. 390 samples were
retained after SmartPCA excluded 20 samples as outliers.
We computed the top five principal component coordi-
nates using SmartPCA to correct for stratification in
association analysis. SmartPCA removed all but one of
the Asian samples and retained Black/African Americans
(Additional file 3); Visual inspection suggests that the
first principal component (PC0), which explains the most
variance in the data, separates the Caucasians and non-
Caucasians reasonably well (setting threshold PC0 < =
0.01 can exclude all non-Caucasians). Finally, we
excluded 52 non-Caucasian samples as outliers; the geno-
mic control variance inflation factor l was 1.00983, sug-
gesting minimal population admixture in the final sample
used for association analysis. We performed association
analysis using age and APOE ε4 genotype as covariate
and did not incorporate principal components. Quantile-
Quantile plots for each of the three test groups with
log10-transformed level of three CSF biomarkers (Addi-
tional file 4 and Additional file 5) suggested that popula-
tion stratification having negligible bias on the genetic
associations (Additional file 6). Finally, for the whole ana-
lysis we performed in the following method section, the
study sample of 390 individuals with three CSF biomar-
kers was used after removing 20 outliers. The level of
three CSF biomarkers was log10-transformed.
Effect of APOE ε4 copy number on CSF biomarker levels
We performed Kruskal-Wallis test of log10-transformed
CSF biomarkers (Ab1-42,T - t a u ,a n dP - t a u 181P)s t r a t i f i e d
by the number of APOE ε4 alleles and the APOE geno-
types across all 390 samples or within each of the three
diagnostic groups.
Association testing of SNPs and CSF analysis
We tested SNP association with the three CSF biomar-
kers (Ab1-42, T-tau, and P-tau181P) by PLINK using sam-
ples and SNP markers passing QC. CSF biomarker
levels were log10-transformed so they become normally
distributed. The association analysis used a full linear
Table 1 Demographic, clinical and biomarker data for
each subject group after removing 20 outliers (n = 390:
Normal, MCI and AD)
Normal (n = 109) Mean
Age (year) 71.7
CSF Ab1-42 levels (pg/ml) 205.8
CSF P-tau181P levels (pg/ml) 25.4
CSF T-tau levels (pg/ml) 71.8
Last MMSE 29
N
Male 59
Female 50
MCI (n = 109) Mean
Age (year) 70
CSF Ab1-42 levels (pg/ml) 170.4
CSF P-tau181P levels (pg/ml) 33.7
CSF T-tau level (pg/ml) 99.5
Last MMSE 26.5
N
Male 72
Female 37
AD (n = 172) Mean
Age (year) 71
CSF Ab1-42 levels (pg/ml) 144.7
CSF P-tau181P levels (pg/ml) 40.3
CSF T-tau levels (pg/ml) 115.3
Last MMSE 21.1
N
Male 105
Female 67
Abbreviations: CSF, cereb al. spinal fluid; MMSE, Mini Mental State
Examination.
Table 2 APOE genotype data for each subject group
(Normal, MCI and AD)
APOE genotype data (after removing outliers: n = 390)
APOE genotype ε2/ε2 ε2/ε3 ε2/ε4 ε3/ε3 ε3/4 ε4/ε4
Normal (n = 109) n 0 18 2 66 21 2
MCI (n = 109) n 0 10 2 47 40 10
AD (n = 172) n 01 3 5 4 8 1 3 3
APOE allele ε2 ε3 ε4
Normal (n = 109) n 20 105 25
MCI (n = 109) n 12 97 52
AD (n = 172) n 4 136 117
APOE genotype data before removing outliers: n = 410)
APOE genotype ε2/ε2 ε2/ε3 ε2/ε4 ε3/ε3 ε3/ε4 ε4/ε4
Normal (n = 119) n 0 20 2 71 24 2
MCI (n = 115) n 0 10 2 52 41 10
AD (n = 176) n 02 3 5 4 8 3 3 4
APOE allele ε2 ε3 ε4
Normal (n = 119) n 22 115 28
MCI (n = 115) n 12 103 53
AD (n = 176) n 5 139 120
Abbreviations: CSF, cerebral spinal fluid.
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of allele dosage (ADD), dominance deviation from addi-
tivity (DOMDEV) (negative means the allele is reces-
sive), and 2-df joint test of both additive and dominance
(GENO_2DF). In addition, we used age (of being
recruited by the study) and APOE ε4g e n o t y p e( n u m b e r
of APOE ε4 allele; 0, 1, 2) as covariates after removing
outliers. To ensure the significance is not due to popula-
tion stratification, we also incorporated the top five PCA
principal components in the linear regression to further
control for the population structure, but found the addi-
tion has very little effect on the statistical significance.
Gene ontology and E-SNP analysis
We carried out gene ontology analysis of SNP associa-
tion results using ALIGATOR (Association LIst Go
AnnoTatOR) [28], to find gene-ontology terms enriched
with significant SNPs. We used p-value cutoff < 10
-3 for
SNPs, 5000 replicate gene lists and 1000 permutations
as parameters to run ALIGATOR. We examined the top
associated SNPs and examined nearby SNPs in linkage
disequilibrium (LD) that are associated with gene
expression from published eQTL studies [29-33].
Results and Discussion
Association of SNPs with CSF biomarkers
We summarize the top SNPs (p-value < 10
-6)w i t ha n d
without using covariates (APOE genotype and age) in
Table 3. Without using covariates, we found some genes
near the top SNPs, including CYP19A1 (rs2899472, p =
1.86 × 10
-7)a n dTOMM40 (rs2075650, p = 3.03 × 10
-7)
from Ab1-42 in normal subject. Several genetic studies
have identified those genes as putative susceptible loci
and genetic variants associated with Alzheimer’s disease
[34,35]. However, close examination of nearby SNPs
showed rs2899472 and rs2075650 were not supported by
nearby SNPs in LD (nearby SNPs in LD are all non-
significant). Because APOE genotypes are strongly asso-
ciated with AD and TOMM40 is physically close to
APOE, we focused on SNPs from adjusted results that
consider APOE genotype and age. Here, we found 10
SNPs significantly associated with CSF biomarker level of
Ab1-42, 3 SNPs from T-tau, and 2 SNPs from P-tau181P at
10
-6 significance level in normal subjects (Figure 1). In
addition, we found 1 SNP significantly associated with
CSF biomarker level of Ab1-42, 3 SNPs from T-tau, and 2
SNPs from P-tau181P at 10
-6 significance level in MCI
subjects (Figure 2). No SNPs were found at 10
-6 signifi-
cance level in AD subjects (Figure 3). For normal sub-
jects, we found genes near the top SNPs, included
CYP19A1 (rs2899472, p = 1.90 × 10
-7), NCAM2
(rs1022442, p = 2.75 × 10
-7)f o rA b1-42 association
and UPP2 (rs2074955, p = 2.07 × 10
-7)f o rP - t a u 181p
association. Again, close examination of SNPs in LD with
rs2899472 (CYP19A1) did not support rs2899472. The
SNP rs1022442 was in close to genome-wide significance,
supported by nearby SNPs (Figure 4), and NCAM2
(neural cell adhesion molecule 2) gene was reported as a
genetic factor related to the progression of AD in the
Japanese population [36]. The Ab1-42 level grouped by
the SNP rs1022442 genotype over all three cohorts (nor-
mal, MCI and AD) supports our finding (Figure 5). Box-
plots of Ab1-42 levels in normal subjects stratified by
rs1022442 genotype showed significant differences
between AA, AB and BB. Previous study indicated an
increased risk associated with rs2899472 in AD patients,
which was amplified in APOE ε4 carriers in their study
[35]. For MCI subjects, we found several genes near the
top SNPs, included FLJ21511 (rs2768975; p = 1.96 × 10
-7,
rs6850199; p = 3.18 × 10
-7) by T-tau association and
CHN2 (rs121724, p = 1.45 × 10
-7), MTUS1 (rs7842088, p
= 2.12 × 10
-7) by P-tau181p association.
Association of APOE with CSF biomarkers
Previous studies suggesting that CSF Ab1-42 and T-tau
levels are correlated with the number of APOE ε4 alleles
[37]. We analyzed the distribution of levels stratified by
diagnosis and the number of APOE ε4i nt h eA D N I
cohort after QC (Figure 6) and reached the same con-
clusion. In the AD group, Ab1-42 level was inversely cor-
related with APOE ε4 allele dose. The APOE e4 was not
associated with T-tau or P-tau181P levels. Analysis of
APOE genotypes showed that ε4/ε4 is associated with
CSF biomarker level of Ab1-42 , T-tau and P-tau181P
(Figure 7).
Pathway analysis of CSF biomarkers
We ran ALIGATOR to identify top gene ontology terms
associated with genes containing SNPs with higher statis-
tical significance, and summarized the results in Addi-
tional file 7. We found cerebral cortex development,
methionine metabolic process, actinin binding, and pal-
lium development to be among the most significant gene
ontology terms associated with CSF biomarker level of
Ab1-42 in normal subjects. Elevation in Ab in the cerebral
cortex has been implicated in the pathophysiology of AD
but its mechanism of action is unknown [38]. It has been
known that mammals have a fully developed cortex, but
the structure it evolved from pallium which is present in
all vertebrates as well as the most primitive ones [39].
The medial pallium forms the precursor of the hippo-
campus. Since hippocampal disruption is one of the ear-
liest signs for AD, pallium development might be
involved in the pathophysiology AD.
E-SNP analysis of CSF biomarkers
We collected eSNPs (SNPs known to be associated with
the expression level of some genes) in several published
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Page 4 of 14Table 3 Linear regression result for SNPs with CSF biomarkers in Normal, MCI and AD subjects (Top SNPs with p-value
<1 0
-6)
Linear regression result without using covariates
Normal: Ab1-42
Chromosome SNP Position A1 TEST BETA STAT P-value Gene Symbol, Gene Name
15 rs2899472 49303347 A GENO_2DF NA 40.21 1.86E-09 CYP19A1, cytochrome p450, family 19, subfamily a,
polypeptide 1
15 rs2899472 49303347 A DOMDEV 0.1791 5.859 5.40E-08 CYP19A1, cytochrome p450, family 19, subfamily a,
polypeptide 1
1 rs11206801 56623274 A GENO_2DF NA 33.14 6.37E-08
1 rs4431886 56624855 C GENO_2DF NA 33.14 6.37E-08
15 rs2899472 49303347 A ADD -0.1407 -5.699 1.11E-07 CYP19A1, cytochrome p450, family 19, subfamily a,
polypeptide 1
19 rs2075650 50087459 G GENO_2DF NA 30.02 3.03E-07 TOMM40, translocase of outer mitochondrial
membrane 40 homolog (yeast)
12 rs10784496 64447238 G GENO_2DF NA 29.98 3.09E-07
7 rs12534221 130938530 A GENO_2DF NA 27.83 9.04E-07
6 rs1727638 72196293 A GENO_2DF NA 27.69 9.71E-07
Normal: T-tau
Chromosome SNP Position A1 TEST BETA STAT P-value Gene Symbol, Gene Name
12 rs1997111 117872301 T GENO_2DF NA 36.66 1.10E-08
12 rs11069178 117852210 C GENO_2DF NA 31.23 1.65E-07
2 rs17189298 119561787 A GENO_2DF NA 29.51 3.90E-07
8 rs2935776 109699079 C GENO_2DF NA 28.81 5.53E-07
8 rs2928826 109683270 T GENO_2DF NA 28.73 5.77E-07
2 rs895401 119584178 G GENO_2DF NA 27.86 8.90E-07
2 rs893769 119556554 C ADD -0.1024 -5.237 8.92E-07
Normal: P-tau181p
Chromosome SNP Position A1 TEST BETA STAT P-value Gene Symbol, Gene Name
18 rs1943816 69209602 C GENO_2DF NA 32.09 1.08E-07
2 rs2074955 158686040 C GENO_2DF NA 32.06 1.09E-07 UPP2, uridine phosphorylase 2
MCI: T-tau
Chromosome SNP Position A1 TEST BETA STAT P-value Gene Symbol, Gene Name
22 rs5998432 31075916 T GENO_2DF NA 27.91 8.696E-07
MCI: P-tau181p
Chromosome SNP Position A1 TEST BETA STAT P-value Gene Symbol, Gene Name
2 rs7558386 227270383 G GENO_2DF NA 32.09 1.08E-07
2 rs7558386 227270383 G DOMDEV 0.242 5.343 5.27E-07
3 rs7631605 37209593 T GENO_2DF NA 27.71 9.60E-07
AD: Ab1-42
Chromosome SNP Position A1 TEST BETA STAT P-value Gene Symbol, Gene Name
21 rs239713 27618347 T GENO_2DF NA 29.03 4.96E-07
AD: T-tau
Chromosome SNP Position A1 TEST BETA STAT P-value Gene Symbol, Gene Name
20 rs4925189 59380439 G DOMDEV 0.1969 5.178 6.35E-07 CDH4, cadherin 4, type 1, R-cadherin (retinal)
AD: P-tau181p
Chromosome SNP Position A1 TEST BETA STAT P-value Gene Symbol, Gene Name
4 rs12643654 96378840 G GENO_2DF NA 29.04 4.95E-07 UNC5C, unc-5 homolog C (C. elegans)
Linear regression result using APOE genotype and age as covariates
Normal: Ab1-42
Chromosome SNP Position A1 TEST BETA STAT P-value Gene Symbol, Gene Name
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Page 5 of 14expression quantitative linkage (eQTL) studies, and
examined regions around significant SNPs (p < 10
-4)
(Additional file 8). We found significant SNPs from
Dixon et al.[ 2 9 ] ,S t r a n g e ret al.[ 3 1 ] ,a n dG i b b set al.
[33], but we could not find any top SNPs that are asso-
ciated with gene expression from other papers [30,32].
Dixon et al.[ 2 9 ]u s e dl y m p h o b l a s t o i dc e l ll i n e s( L C L s )
derived from children both with and without asthma.
NCAM2 (Neural Cell Adhesion Molecule 2)
We obtained strong evidence that NCAM2 genotypes
are associated with Ab1-42 levels. NCAM2 (Ensemble:
ENSG00000154654, OMIM: 602040;) is a 541Kb gene at
21q21.1 with no known alternative spicing forms.
Novartis SymAtlas human tissue survey shows the gene
(Affymetrix probeset ID 205669_at) is ubiquitously
expressed and is highly expressed in cardiac myocytes,
Table 3: Linear regression result for SNPs with CSF biomarkers in Normal, MCI and AD subjects (Top SNPs with
p-value < 10
-6) (Continued)
15 rs2899472 49303347 A GENO_2DF NA 53.98 1.90E-12 CYP19A1, cytochrome p450, family 19, subfamily a,
polypeptide 1
15 rs2899472 49303347 A ADD -0.1393 -6.925 3.85E- 0 CYP19A1, cytochrome p450, family 19, subfamily a,
polypeptide 1
15 rs2899472 49303347 A DOMDEV 0.1614 6.425 4.15E-09 CYP19A1, cytochrome p450, family 19, subfamily a,
polypeptide 1
21 rs1022442 21277717 A GENO_2DF NA 30.21 2.75E-07 NCAM2, neural cell adhesion molecule 2
10 rs2493624 19102262 G GENO_2DF NA 28.61 6.14E-07
10 rs11015839 19042893 A GENO_2DF NA 28.51 6.45E-07 ARL5B, adp-ribosylation factor-like 5b
10 rs11015860 19045045 G GENO_2DF NA 28.51 6.45E-07
1 rs10911736 183689227 A GENO_2DF NA 28.16 7.69E-07
10 rs11015839 19042893 A ADD -0.1151 -5.257 7.87E-07
10 rs11015860 19045045 G ADD -0.1151 -5.257 7.87E-07
10 rs11015939 19057948 A ADD -0.1243 -5.219 9.25E-07
10 rs2495832 19114467 G ADD -0.1243 -5.219 9.25E-07
6 rs12203791 67778209 T GENO_2DF NA 27.68 9.76E-07
10 rs10763625 19074957 T ADD -0.124 -5.206 9.78E-07
Normal: T-tau
Chromosome SNP Position A1 TEST BETA STAT P-value Gene Symbol, Gene Name
12 rs1997111 117872301 T GENO_2DF NA 30.74 2.11E-07
2 rs17189298 119561787 A GENO_2DF NA 27.92 8.66E-07
18 rs1021599 28469054 T GENO_2DF NA 27.88 8.81E-07
Normal: P-tau181p
Chromosome SNP Position A1 TEST BETA STAT P-value Gene Symbol, Gene Name
18 rs1943816 69209602 C GENO_2DF NA 31.43 1.50E-07
2 rs2074955 158686040 C GENO_2DF NA 30.78 2.07E-07 UPP2, uridine phosphorylase 2
MCI: Ab1-42
Chromosome SNP Position A1 TEST BETA STAT P-value Gene Symbol, Gene Name
10 rs2986971 30136634 G GENO_2DF NA 31.88 1.20E-07
10 rs2986971 30136634 G ADD 0.08328 5.228 8.88E-07
MCI: T-tau
Chromosome SNP Position A1 TEST BETA STAT P-value Gene Symbol, Gene Name
4 rs2768975 48724658 G GENO_2DF NA 30.89 1.96E-07 FLJ21511, hypothetical protein flj21511
4 rs6850199 48695607 A GENO_2DF NA 29.93 3.18E-07 FLJ21511, hypothetical protein flj21511
18 rs1445093 48024821 C GENO_2DF NA 28.14 7.75E-07
MCI: P-tau181p
Chromosome SNP Position A1 TEST BETA STAT P-value Gene Symbol, Gene Name
7 rs121724 29207970 G GENO_2DF NA 31.49 1.45E-07 CHN2, chimerin (chimaerin) 2
8 rs7842088 17629409 G GENO_2DF NA 30.73 2.12E-07 MTUS1, mitochondrial tumor suppressor 1
Abbreviations: SNP, single-nucleotide polymorphism; ADD, additive effects of allele dosage; DOMDEV, dominance deviation from additivity, rather specifying that
a particular allele is dominant or recessive; GENO_2DF, a 2 df joint test of both additive and dominance; A1, tested allele (minor allele); BETA, regression
coefficient; STAT, coefficient t-statistic.
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NCAM2 has higher expression levels in prefrontal cor-
tex, superior cervical ganglion, and hypothalamus. The
transcript (Ensembl: ENST00000400546) consists of 18
exons and encodes a 93 k-Da, 835-residue plasma mem-
brane protein (NP_004531.2). The NCAM2 protein
architecture includes 5 IgC2 (Immunoglobulin C-2 type)
domains followed by two FN3 (fibronectin type 3)
domains and a transmembrane domain. The gene is
conserved in chimpanzee, dog, cow, mouse, rat, chicken,
zebrafish, and fruit fly; the eight-domain protein archi-
tecture is also conserved in all these organisms except
for cow which has only four IgC2 domains. Little is
known about NCAM2 except that the protein interacts
with prion protein [40] and estrogen receptor 1 (ESR1)
[41], is involved in neuron adhesion and fasciculation of
neurons, and may be involved in AD [36], prion disease,
and Down syndrome [42,43].
TOMM40 (translocase of outer mitochondrial membrane
40 homolog (yeast)) and CYP19A1 (Cytochrome P450,
family 19, subfamily A, polypeptide 1)
It is interesting to note that we found no significant
association in APOE (rs769451, chr19: 50102751, p =
0.6682 for association with Ab1-42 l e v e li nn o r m a ls u b -
jects), but a SNP with strong association in the nearby
TOMM40 (intronic SNP rs2075650, chr19:50087459, p
=3 . 0 3×1 0
-7 for association with Ab1-42 level in normal
Figure 1 Manhattan plots of the quantitative trait (CSF biomarkers: T-tau, P-tau181P and Ab1-42) genome wide association analysis in
normal subjects. Colors on x-axis indicate an autosomal chromosome (from chromosome 1 to chromosome 22). The y-axis indicates p-values
(-log10(observed p-values)). Red arrows indicate rs2899472 on chromosome 15 and blue arrow indicates rs1022442 on chromosome 21.
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were not included in the regression. The TOMM40
gene is related to how easily molecules can get into and
out of the surface of the mitochondria, the energy cen-
ter of cells. This gene is a transporter of proteins across
the mitochondrial membrane, and Sortillin-related
receptor, which functions to partition amyloid precursor
protein away from b-secretase and -secretase [44]. This
is consistent with observations that levels are reduced in
the brains of patients with Alzheimer’s disease and MCI
[44-46]. The TOMM40 gene has been reported in
numerous studies in the study of AD genetics; for exam-
ple, Yu et al. [47] reported possibility that loci in the
TOMM40 g e n em a yh a v eal e s se f f e c to nt h er i s kf o r
LOAD in Caucasians [47], and recently Roses et al. [48]
found evidence supporting a poly-T polymorphism
(rs10524523, chr19:50094889) in TOMM40 affecting the
AD age of onset in two independent clinical cohorts.
The potential association of TOMM40 and Ab1-42 may
be how the gene affects the risk and onset age of AD
and should be further investigated.
The CYP19A1 gene is localized on chromosome
15q21.2 and spans 123 kb. This gene encodes a member
of the cytochrome P450 superfamily of enzymes. Cyto-
chrome P450 aromatase is an enzyme that catalyses the
conversion of androgens, such as testosterone, to oestro-
gens, which act as sex steroid hormones but also func-
tion during growth and differentiation. There are high
Figure 2 Manhattan plots of the quantitative trait (CSF biomarkers: T-tau, P-tau181P and Ab1-42) genome wide association analysis in
MCI subjects. Colors on x-axis indicate an autosomal chromosome (from chromosome 1 to chromosome 22). The y-axis indicates p-values
(-log10(observed p-values)).
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Page 8 of 14levels of expression in both the gonads and the brain
[35]. Huang et al. [35] indicated an increased risk asso-
ciated with SNP rs2899472 in the total number of AD
patients, which was amplified in APOE ε4 carriers.
Conclusions
Our analysis of the ADNI genome-wide association study
identified several putative loci that are in genetic associa-
tion with Ab1-42, T-tau and P-tau181P levels in cerebrosp-
inal fluids. In particular an intronic SNP rs1022442 of
gene NCAM2 is close to genome-wide significance in
association with Ab1-42 in normal subjects. Although the
gene is poorly characterized in the literature, prior stu-
dies have implicated roles of NCAM2 in prion disease,
Down syndrome, and AD. Our findings suggest NCAM2
could be part of the pathway on the pathogenesis of
senile plaques in human brains with AD.
With only 119 normal subjects and 410 overall, the
GWAS dataset is clearly underpowered. The most sig-
nificant associations were identified using normal sub-
jects since the variances of the CSF biomarker levels are
much smaller in MCI and AD subjects due to dementia.
Nonetheless, increasing the number of CSF biomarker
measurements is challenging especially for normal sub-
jects. An alternative that will substantially increase the
sample size is to examine protein levels in blood instead
of CSF, given levels of these proteins in blood are infor-
mative about AD pathology or prognosis [49].
Figure 3 Manhattan plots of the quantitative trait (CSF biomarkers: T-tau, P-tau181P and Ab1-42) genome wide association analysis in
AD subjects. Colors on x-axis indicate an autosomal chromosome (from chromosome 1 to chromosome 22). The y-axis indicates p-values
(-log10(observed p-values)).
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Page 9 of 14Figure 4 Upper image shows genes in linkage disequilibrium with the SNP rs1022442 and lower plot shows the distribution of SNP
rs1022442 and nearby SNPs. In lower plot, the x-axis indicates loci on chromosome 21 and y-axis indicates p-values (-log10(observed
GENO_2DF p-values)). Green arrow indicates rs1022442 (p = 2.75 × 10
-7) on loci 21277717 and pink arrow indicates rs2826629 (p = 8.40 × 10
-5)
on loci 21265887.
Figure 5 Boxplots of Ab1-42 levels in normal, MCI and AD subjects stratified by rs1022442 genotype. The x-axis indicates AA, AB and BB
respectively.
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trait linkage of biomarkers via genome-wide screening
can reveal additional insights into the mechanism that
connects known genetic factors to the disease [50].
Moving along this path requires further efforts by the
research community towards larger sample size and
accrual of additional biomarkers in AD and other neu-
rodegenerative disorders.
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